Trial Outcomes & Findings for Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax (NCT NCT02987660)

NCT ID: NCT02987660

Last Updated: 2019-01-14

Results Overview

Manifest refraction cylinder was measured monocularly (each eye separately) at 3 or 4 meters (m) under photopic lighting conditions using a phoropter and Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The manifest refraction at 4 m or 3 m was adjusted for optical infinity by adding -0.25 D to the sphere value. Both eyes contributed to the analysis. Since the study was terminated early, inferential statistics could not be completed.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

21 participants

Primary outcome timeframe

Month 3

Results posted on

2019-01-14

Participant Flow

Subjects were recruited from 1 study center located in France.

Of the 21 enrolled, 1 subject was exited as a screen failure prior to randomization. This reporting group includes all randomized subjects (20).

Participant milestones

Participant milestones
Measure
LASIK
Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
SMILE
Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
Overall Study
STARTED
10
10
Overall Study
COMPLETED
0
0
Overall Study
NOT COMPLETED
10
10

Reasons for withdrawal

Reasons for withdrawal
Measure
LASIK
Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
SMILE
Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
Overall Study
Study terminated by sponsor
10
10

Baseline Characteristics

Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
LASIK
n=10 Participants
Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
SMILE
n=10 Participants
Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
Total
n=20 Participants
Total of all reporting groups
Age, Customized
< 65 years
10 Participants
n=99 Participants
10 Participants
n=107 Participants
20 Participants
n=206 Participants
Age, Customized
≥ 65 years
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Sex: Female, Male
Female
7 Participants
n=99 Participants
6 Participants
n=107 Participants
13 Participants
n=206 Participants
Sex: Female, Male
Male
3 Participants
n=99 Participants
4 Participants
n=107 Participants
7 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
3 Participants
n=99 Participants
5 Participants
n=107 Participants
8 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
6 Participants
n=99 Participants
5 Participants
n=107 Participants
11 Participants
n=206 Participants

PRIMARY outcome

Timeframe: Month 3

Population: ITT with non-missing data

Manifest refraction cylinder was measured monocularly (each eye separately) at 3 or 4 meters (m) under photopic lighting conditions using a phoropter and Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The manifest refraction at 4 m or 3 m was adjusted for optical infinity by adding -0.25 D to the sphere value. Both eyes contributed to the analysis. Since the study was terminated early, inferential statistics could not be completed.

Outcome measures

Outcome measures
Measure
LASIK
n=10 Eyes
Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
SMILE
n=14 Eyes
Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
Percentage of Eyes With Manifest Refraction Cylinder Less Than or Equal to 0.5 Diopter (D) at 3 Months
60 percentage of eyes
Interval 26.2 to 87.8
100.0 percentage of eyes
Interval 76.8 to 100.0

SECONDARY outcome

Timeframe: Month 3

Population: ITT with non-missing data

Manifest refraction cylinder was measured monocularly at 3 or 4 meters under photopic lighting conditions using a phoropter and ETDRS chart. The manifest refraction at 4 m or 3 m was adjusted for optical infinity by adding -0.25 D to the sphere value. Both eyes contributed to the analysis. Since the study was terminated early, inferential statistics could not be completed.

Outcome measures

Outcome measures
Measure
LASIK
n=10 Eyes
Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
SMILE
n=14 Eyes
Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
Mean Manifest Refraction Cylinder at 3 Months
-0.575 Diopters
Standard Deviation 0.4091
-0.232 Diopters
Standard Deviation 0.1539

SECONDARY outcome

Timeframe: Month 3

Population: ITT with non-missing data

Uncorrected (without spectacles or other visual corrective devices) Visual Acuity (UCVA) testing was conducted monocularly in photopic conditions without glare at 3 or 4 meters. Visual Acuity (VA) is measured in "logarithm of the minimum angle of resolution" (logMAR). A lower logMAR value indicates better visual acuity. The Precision Vision illuminator cabinets and ETDRS charts were used. For subjects who could not read English letters, a numerical, Tumbling E logMAR chart was used. Since the study was terminated early, inferential statistics could not be completed.

Outcome measures

Outcome measures
Measure
LASIK
n=10 Eyes
Topography Guided LASIK with WaveLight EX500 excimer laser system in bilateral surgery
SMILE
n=14 Eyes
Small incision lenticular extraction (SMILE) with VisuMax laser in bilateral surgery
Mean Uncorrected Visual Acuity (UCVA) at 3 Months
-0.100 logMAR
Standard Deviation 0.1360
-0.164 logMAR
Standard Deviation 0.0769

Adverse Events

LASIK

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

SMILE

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sr. Global Brand Medical Affairs Lead, CDMA Surgical

Alcon, A Novartis Division

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
  • Publication restrictions are in place

Restriction type: OTHER